Montpellier Vectorology Platform

Montpellier Vectorology Platform

Overview of the Platform and Its Facilities

PVM : Presentation

The Montpellier Vectorology Platform (PVM) is dedicated to the production of recombinant viral particles for any requesting laboratory. Viral vectors enable efficient, reproducible, and targeted gene expression in various cell types.

The particles produced by PVM are based on several viral systems:

  • Human and canine adenoviruses
  • Lentivirus / Retrovirus
  • Adeno-Associated Viruses (AAV)

The use of adenoviruses, AAVs, or lentiviruses has advantages and limitations linked to the intrinsic properties of each vector, including:

  • Their episomal (non-integrating) or integrative nature,
  • The onset and duration of transgene expression,
  • Their cellular tropism, broad or specific,
  • The size of the genetic material that can be delivered.

These particles can infect cell lines, primary cultures, and/or be injected directly in vivo. All these factors must be considered to choose the vector best suited for a project.

Our Missions

Design

Guide laboratories toward the type of viral particles best suited to their experimental objectives and biological constraints.

Produce

Ensure the production of reliable, high-quality recombinant viral particles, ready to be used in various types of experiments.

Support

Advise and guide researchers in the use of vectors, taking into account the specific properties of each virus and the intended applications.

Applications

  • Labeling of specific cell cohorts, lineage, and network studies
  • Control of neuronal activity
  • Gain- and loss-of-function approaches to identify the role of different genes
  • Vaccines
  • Gene therapy

Learn More

PVM : Facilities

The platform consists of two technical facilities, located in two institutes in Montpellier. We have relied on the expertise of local research teams to offer our services to the entire academic and private scientific community. In 2008, the first facility was established at IGF, specializing in Lentivirus and AAV.

In 2013, the Human and Canine Adenovirus facility joined the PVM platform. It is located at IGMM.

The Lentivirus and AAV Facility

The PVM Lentivirus / AAV facility offers production of lentiviral, retroviral, and AAV vectors according to validated procedures, including purification and titration. It supports users in selecting the systems and production formats suitable for in vitro and in vivo applications.

>> Learn more

The Human and Canine Adenovirus Facility

The PVM Adenovirus facility provides production of human adenovectors (HAdV 2 and 5) and canine adenovectors (CAV-2), as well as helper-dependent or custom vectors. Productions are carried out according to protocols ensuring the safety and quality of the delivered particles.

>> Learn more

PVM: Organization chart

Direction de la plateforme PVM

    Responsable Scientifique :

  • Arnaud MONTEIL
    • (CR, CNRS, 5%)

    Responsable opérationnel :

  • Celine LEMMERS
    • (IR, INSERM, 10%)
+-

Comité de Direction

  • Eric J. KREMER
  • Celine LEMMERS
  • Arnaud MONTEIL
+-

Comité d'orientation scientifique et technique

    Experts locaux :

  • Yea-Lih LIN
    • (IGH, Montpellier)
  • Clément METTLING
    • (IGH, Montpellier)
+-

Lentivirus et virus adéno-associés

    Responsable Scientifique :

  • Arnaud MONTEIL (CR, CNRS, 10%)

    Responsable Technique :

  • Celine LEMMERS (IR, INSERM, 90%)
+-

Adenovirus humain et canin

    Responsable Scientifique :

  • Eric J. KREMER (DR, INSERM, 5%)

    Responsable Technique :

  • Marina LAVIGNE (IE, CNRS, 100%)

    Personnel plateau permanent :

  • Bertrand BEUCHER (IR, UM, 100%)
+-

Any questions?

For any inquiries regarding the PVM platform, our activities, or our services, please do not hesitate to contact us.